Osteoporosis
- 1 August 2004
- journal article
- review article
- Published by Wolters Kluwer Health in Clinical Orthopaedics and Related Research
- Vol. 425, 126-134
- https://doi.org/10.1097/01.blo.0000132404.30139.f2
Abstract
Osteoporosis is the most common metabolic bone disorder and remains an increasingly significant problem, affecting 200 million individuals worldwide. Osteoporosis often is undertreated and underrecognized, in part because it is a clinically silent disease until it manifests in the form of fracture. Sufficient recognition of the disease and its appropriate medical and nonmedical treatment are essential. Treatments including calcium and vitamin D, the bisphosphonates, estrogen, selective estrogen receptor modulators, calcitonin, parathyroid hormone, balance and exercise training programs, and the minimally invasive spine procedures vertebroplasty and kyphoplasty comprise a comprehensive multidisciplinary approach in the treatment of osteoporosis. The data suggest that medical treatment of osteoporosis is increasing each year as physician awareness is heightened. Nonmedical treatment of osteoporosis complements the appropriate pharmacologic treatment, and these treatments should be used together to maximize outcomes for patients with osteoporosis. Fracture data for the intravenous biphosphonates and the long-term effects of the minimally-invasive spine procedures vertebroplasty and kyphoplasty have yet to be reported in the literature, but the effects on bone mineral density, and short-term results of these procedures, respectively, have been promising.Keywords
This publication has 59 references indexed in Scilit:
- The Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Postmenopausal OsteoporosisNew England Journal of Medicine, 2003
- A Randomized Double-Blind Trial to Compare the Efficacy of Teriparatide [Recombinant Human Parathyroid Hormone (1–34)] with Alendronate in Postmenopausal Women with OsteoporosisJournal of Clinical Endocrinology & Metabolism, 2002
- Evaluation of Decision Rules for Referring Women for Bone Densitometry by Dual-Energy X-ray AbsorptiometryJAMA, 2001
- Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention TrialJournal of Clinical Endocrinology & Metabolism, 2000
- A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures studyAmerican Journal Of Medicine, 2000
- Hip protectors improve falls self-efficacyAge and Ageing, 2000
- Understanding the Female Athlete Triad: Eating Disorders, Amenorrhea, and OsteoporosisJournal of School Health, 1999
- Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fracturesThe Lancet, 1996
- Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly womenBMJ, 1994
- Vitamin D3and Calcium to Prevent Hip Fractures in Elderly WomenNew England Journal of Medicine, 1992